Finasteride in 2026: What’s Still True, What Changed, What’s Overblown | Dr. Aly Podcast

Main ideas / lessons from the video

• Finasteride dosing should be individualized, not treated as a one-size-fits-all “standard 1 mg” regimen.
• Patient selection matters: the best candidates are those who still have usable follicles (not just advanced balding), are mature enough, and have manageable anxiety/expectations.
• Lower doses are presented as a “sweet spot” for long-term maintenance, while potentially reducing side-effect risk and “exhaustion” over time.
• Timing expectations are crucial: early shedding/worsening can occur before improvement; meaningful assessment is typically after 6–7 months.
• Side effects are categorized by timing and type (non-sexual early vs sexual later), and dose adjustments can help.
• Finasteride remains central even for hair transplant patients if the underlying issue is androgenetic alopecia; transplants don’t change genetics.
• Dutasteride is framed as an escalation tool, used cautiously and not as a default alternative to daily finasteride.
• When trying to conceive, coordination with fertility evaluation is emphasized; do not automatically blame finasteride for infertility.

---

Methodology / instructions (structured as bullet points)

A) How to decide if someone is a good candidate for finasteride

Step 1: Confirm follicles exist using trichoscopy

• Use trichoscopy to estimate follicle/hair miniaturization status.
• Categorize hair size:
  • >60 microns = larger (more favorable)
  • 30–60 microns = miniaturizing (best candidates)
  • <30 microns = highly miniaturized
    • If <30 microns, he gives limited hope (may still be a “bonus” response).
• Key idea: finasteride helps follicles that can still respond; self-medication in advanced loss may disappoint.

Step 2: Consider developmental maturity (age)

• General “safe” guideline: around 21–22.
• If 19–20:
  • Prefer bringing parents to compare physical development (height vs parents).
  • Assess sexual development (secondary sexual characteristics, sexual organs, facial hair/beard, etc.).
  • Requires stricter monitoring and more clinical judgment.
• Rationale: avoid prematurely interfering with development of male sexual characteristics.

Step 3: Assess psychological readiness / anxiety

• Higher anxiety/fear → may delay starting finasteride.
• Use in-person observation (fidgeting, hesitation, inability to answer clearly).
• Use gentle questioning:
  • “Tell me what you know about finasteride”
  • “What are your three biggest fears?”
  • “What are your expectations?”
• If mindset remains strongly negative: do counseling first, potentially months.
• Message: no rush—fearful patients often need more reassurance and time.

---

B) Dosing approach (dose selection and titration)

Starting point (history-based evolution)

• He began with 1 mg (standard textbook approach).
• Over years, he shifted toward 0.5 mg daily as a “sweet spot.”

General dosing strategy

• Default: 0.5 mg finasteride daily
• If patient anxiety is high:
  • Consider 0.5 mg once per week, then gradually increase:
    • Example ramp: once/week (2 weeks) → twice/week (2 weeks) → 3 times/week (additional weeks), approaching alternate-day dosing.

Alternate/lowest effective dosing

• Very low-dose option discussed:
  • 0.5 mg alternate days (stated as ~0.25 mg/day)
• Trial response-guided adjustment (can go back up to 0.5 mg if needed).

Why not aggressively cut pills

• He prefers not to create very small fractions (e.g., from a 1 mg tablet into many tiny pieces).
• Reasons given:
  • tablets may not be perfectly homogeneous in active content,
  • splitting creates crumbs → potential loss/inconsistent dosing.

Compounding pharmacy option (preferred where available)

• Use independent compounding to make customized dose capsules (e.g., ~0.4–0.5 mg).
• Helpful where dose flexibility is needed.

---

C) How long to wait before judging results

Ballpark timeline (common course)

• Weeks 4–6 (1–1.5 months): miniaturized hair sheds; may look worse.
• Month 2: shedding typically stops or reduces.
• Month 3: stabilization; possible early regrowth feelings.
• Month 4: some growth may be seen.
• Months 5–6: more noticeable improvement.
• Months 6–7: “significant improvement” (not always full).

Assessment rule

• Advise patients to wait 6–7 months before judging.
• Early temporary worsening is expected.

Outliers

• Rare cases may show no meaningful improvement until month 14–15, then improve by month 18–24.
• Typical plateau: around month 10–12 (maintenance thereafter).

---

D) Side effects framework (timing + type) and what to do

Two broad categories

• Non-sexual/transient (early): often first 7–10 days to first few weeks
• Sexual (dose adjustment related): often shows up after ~3–4 weeks

Non-sexual side effects he mentions

• Testicular pain (noted within first ~2 weeks)
• Leg muscle pain

Management for early non-sexual effects

• Reduce dose or take a break, restart lower, then titrate.
• He notes that sometimes symptoms settle by crossing ~2 weeks (patients may stop early if they panic).

Sexual side effects—risk context

• More likely in patients with:
  • higher anxiety,
  • previous history of low libido or ED.

Possible additional triggers for sexual side effects (beyond anxiety)

• Younger men: sleep deprivation, stress/inflammation (more cortisol), lifestyle imbalance.
• Middle-age: natural endocrine changes across decades (he claims ~10% adjustments in DHT/testosterone per decade), plus compounded lifestyle factors.
• He gives examples:
  • Lack of sleep for 2–3 days affects morning erections/enjoyment.
  • More than 2–3 drinks affects sexual performance/enjoyment.

Key principle

• Sexual side effects appearing after weeks suggests a need to find a different “sweet spot” dose.

---

E) Pregnancy / family planning counseling approach

Not an automatic contraindication

• He does not present finasteride as an automatic contraindication.
• He cites patient experiences: wives become pregnant, and he reports no specific deformities.

Broader fertility factors

• He emphasizes lifestyle exposures (pressure, pollution, nutrition) that may contribute to subfertility.

Practical guidance if actively trying

• If no sexual side effects (desire/libido/erection functioning well), he suggests it may be reasonable to continue.
• If actively trying:
  • Give ~6 months from when planning begins.
• If not working by ~6 months:
  • Consult a fertility doctor and evaluate both partners.
  • Check sperm beyond “just count/motility” thinking:
    • he cites only a portion is truly highly motile (example: ~15–20%),
    • so poor motility may exist even if men feel “fertile.”
  • Also check inflammation and nutritional/endocrine markers:
    • thyroid, vitamin D, ferritin (iron), CRP, homocysteine.

Management options if concerns arise

• Don’t assume finasteride is the sole cause.
• Consider switching temporarily to alternatives (he mentions possible topical finasteride).

---

F) “Plan B” if someone can’t take oral finasteride

Strategy

• Go super low dose orally first (example: 0.5 mg once weekly).
• Add topical finasteride (where used).
• Frame goal as: slow maintenance, not regrowth.

Family/partner involvement

• He stresses partner involvement to avoid resentment and strain that can affect fertility and compliance.
• He recommends discussing family planning together as a couple.

---

G) When to consider dutasteride (escalation logic)

Historical pattern

• In some men (especially after earlier 1 mg finasteride), after 2–3 years they may develop “resistance” with renewed thinning.

Challenges common assumptions

• He claims daily dutasteride can be as bad or worse for sexual side effects than finasteride.
• He mentions possible downsides:
  • longer clearance if sexual side effects happen,
  • higher risk of gynecomastia,
  • possible depression/anxiety on daily doses.

When he uses dutasteride

• Switch only if:
  • finasteride response is poor,
  • (often) genetic testing to compare likely response.

Genetic test approach

• Example test mentioned: Fagron Genomics.
• Example interpretation:
  • “80% response to finasteride, 95% to dutasteride” → supports switching.

Dosing conservatism

• Never goes straight to daily dutasteride.
• Start around:
  • twice weekly, titrate carefully (up to 3 times/week, sometimes 4).
• He references a study claiming 2–3×/week dutasteride can be effective.

---

H) How he explains long-term finasteride “deterioration/exhaustion”

Proposed mechanism

• Finasteride prolongs anagen and reverses miniaturization.
• He suggests accelerated hair growth may overtax follicle capacity (stem cell/growth factor supply).
• This could lead to “exhaustion” around year 2–3.

Why lower dose might help

• Lower dosing may avoid “pressing the gas pedal.”
• Result: less frequent deterioration and fewer needs for interventions (PRP/exosomes/polynucleotides).

---

I) Hair transplant and whether finasteride is required

Different cases

• Not genetic/androgenetic cases (e.g., high forehead/corners present from birth as a deformity):
  • finasteride not part of the plan.
• Androgenetic alopecia:
  • transplant is a “second chance” to place hair, but genetics remain.
  • donor hairs aren’t 100% immune; they can still miniaturize later.
  • therefore, he encourages commitment to finasteride (or equivalent DHT control).

Recommendation for many young transplant candidates

• Prevention of further miniaturization in existing hair and gradual donor sensitivity.

Cutoff age for surgery (for him)

• Around 23 is his cutoff (not a hard rule).
• For severe Norwood 3–4 at age ~23:
  • start finasteride,
  • wait 6–9 months,
  • decide later based on response and commitment.

---

J) His “if it were my family” message

• If it were his brother/son, he would tell them to act early while it’s “scientifically proven, FDA approved, cheap, and works.”
• He frames it as doing something before it’s too late.
• He uses a lighthearted motivational approach (sarcastic/“cheeky” teasing) to provoke compliance and self-care.

---

Speakers / sources featured

Speakers

• Matt (host/interviewer)
• Dr. Ali (hair transplant surgeon from Malaysia; primary source of the medical viewpoints in the subtitles)

Sources mentioned (non-speaker entities)

• Canfield (used for trichoscopy “Hair Matrix” in his practice)
• Fagron / Fagron Genomics (genetic testing mentioned)
• Mentions of medical authorities/labels in passing: FDA-approved (general statement)
• Mentions of studies in passing (e.g., dutasteride dosing effectiveness study “from last year”), but no specific study title/author provided